The potential to use a simple blood test to guide physicians in monitoring cancer therapies, detect early cancers, serve as a companion diagnostic to guide targeted therapeutics and predict the likely course or outcomes of disease in patients has spurred a lot of interest and innovation. Here's a look at emerging companies hoping to make an impact, including insights from interviews conducted with C-Level visitors at the recent Liquid Biopsy Conference in San Francisco. This is the second of a two-part series focusing on the global liquid biopsy market.
[Editor's note:This is the second of a two-part series on the liquid biopsy market. Check out the first article, providing a market overview a look at some of the larger players, here.]
Dozens of companies are trying to compete in liquid biopsy, but which ones will become successful in